Matsuyama Hideyasu, Pan Yi, Yoshihiro Satoru, Kudren David, Naito Katsusuke, Bergerheim Ulf S R, Ekman Peter
Department of Urology, Yamaguchi University School of Medicine, Minamikogushi, Ube, Japan.
Prostate. 2003 Feb 1;54(2):103-11. doi: 10.1002/pros.10173.
We lack simple and reliable diagnostic tools to predict pathological staging as well as further progression of prostate cancer in individual cases.
We studied deletions on 8p (8p22 and 8p23-pter), 10q (10q24-qter), and 16q (16q24) by fluorescence in situ hybridization in 53 specimens from patients with prostate cancer, and compared the status of these deletions with various clinical parameters. Forty-five cases were further evaluated regarding disease progression with a median follow-up period of 62 months.
The overall frequencies of deletions for 8p, 10q, and 16q were 74, 55, and 55%, respectively. The frequency of 8p and 16q deletions increased significantly in parallel with tumor grade (P < 0.01 and < 0.05, respectively), while that of 10q deletions did not. Patients whose tumors showed 8p22 deletions had a significantly higher frequency in pT3 or metastatic tumors than in pT2 tumors. Patients whose tumors showed both 8p22 and 16q24 deletions had a significantly higher frequency of nodal metastases than non-metastases. A Cox hazard proportional model revealed 8p22 deletion to be the strongest parameter predictive of disease progression (hazard ratio = 6.624; P = 0.0001).
Estimation of 8p22 and 16q24 deletions may serve as a genetic diagnosis for predicting pathological staging as well as disease progression in prostate cancer.
我们缺乏简单可靠的诊断工具来预测前列腺癌个体病例的病理分期以及疾病进展。
我们通过荧光原位杂交研究了53例前列腺癌患者标本中8号染色体短臂（8p22和8p23 - pter）、10号染色体长臂（10q24 - qter）和16号染色体长臂（16q24）的缺失情况，并将这些缺失状态与各种临床参数进行比较。对45例患者进行了进一步的疾病进展评估，中位随访期为62个月。
8号染色体短臂、10号染色体长臂和16号染色体长臂缺失的总体频率分别为74%、55%和55%。8号染色体短臂和16号染色体长臂缺失的频率与肿瘤分级显著平行增加（分别为P < 0.01和< 0.05），而10号染色体长臂缺失的频率则不然。肿瘤显示8p22缺失的患者中，pT3期或转移性肿瘤的频率显著高于pT2期肿瘤。肿瘤同时显示8p22和16q24缺失的患者发生淋巴结转移的频率显著高于未发生转移的患者。Cox风险比例模型显示8p22缺失是疾病进展最强的预测参数（风险比 = 6.624；P = 0.0001）。
评估8p22和16q24缺失可作为预测前列腺癌病理分期及疾病进展的基因诊断方法。
